GCM
EDIT icon

Graham Capital Management’s Editas Medicine EDIT Stock Holding History

Graham Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
+41,472
New +$121K ﹤0.01% 1109
2026
Q1 		– Sell
-139,904
Closed -$287K – 1255
2025
Q4 		$287K Buy
139,904
+72,820
+109% +$210K 0.01% 878
2025
Q3 		$233K Buy
67,084
+26,451
+65% +$73.8K ﹤0.01% 980
2025
Q2 		$89.4K Buy
+40,633
New +$66.5K ﹤0.01% 1215
2024
Q2 		– Sell
-62,106
Closed -$461K – 1118
2024
Q1 		$461K Buy
62,106
+46,725
+304% +$388K 0.01% 651
2023
Q4 		$156K Sell
15,381
-16,975
-52% -$149K ﹤0.01% 872
2023
Q3 		$252K Sell
32,356
-732
-2% -$6.28K 0.01% 779
2023
Q2 		$272K Buy
+33,088
New +$288K 0.01% 724
2022
Q4 		– Sell
-158,186
Closed -$1.94M – 1104
2022
Q3 		$1.94M Buy
158,186
+14,106
+10% +$220K 0.08% 234
2022
Q2 		$1.7M Buy
+144,080
New +$1.93M 0.07% 260
2022
Q1 		– Sell
-12,429
Closed -$329K – 920
2021
Q4 		$329K Buy
+12,429
New +$428K 0.01% 287

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Graham Capital Management's EDIT Position: Q2 2026 in Review

Graham Capital Management opened a new position in Editas Medicine (EDIT) in Q2 2026: 41,472 shares worth $134K. The stake represents ﹤0.01% of the portfolio and ranks #1109 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in EDIT as recently as Q4 2025.

Graham Capital Management first reported a position in EDIT in Q4 2021 and has held it in 11 quarters since. The position peaked at $1.94M in Q3 2022. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Graham Capital Management held 41,472 shares of Editas Medicine worth $134K as of Q2 2026.
  • Editas Medicine was a new Graham Capital Management position in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1109 holding.
  • Graham Capital Management first reported a position in Editas Medicine in Q4 2021 and has held it in 11 quarters since.
  • Graham Capital Management's Editas Medicine position peaked at $1.94M in Q3 2022.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.